The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kozma, N.
Right arrow Articles by Szekeres-Bartho, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kozma, N.
Right arrow Articles by Szekeres-Bartho, J.
The Journal of Immunology, 2006, 176: 819-826.
Copyright © 2006 by The American Association of Immunologists

Progesterone-Induced Blocking Factor Activates STAT6 via Binding to a Novel IL-4 Receptor1

Noemi Kozma*, Melinda Halasz*, Beata Polgar*, Tobias G. Poehlmann, Udo R. Markert, Tamas Palkovics*, Marton Keszei||, Gabriella Par*, Katalin Kiss{dagger}, Jozsef Szeberenyi{dagger}, Laszlo Grama{ddagger} and Julia Szekeres-Bartho2,*,§

* Department of Medical Microbiology and Immunology, {dagger} Department of Biology, {ddagger} Department of Biophysics, and § Reproductive and Tumor Immunology Research Group of the Hungarian Academy of Sciences, Pecs University, Pecs, Hungary; Friedrich-Schiller University, Jena, Germany; and || Department of Genetics, Cellular, and Immunobiology, Semmelweis University, Medical School, Budapest, Hungary


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Progesterone-induced blocking factor (PIBF) induces Th2-dominant cytokine production. Western blotting and EMSA revealed phosphorylation as well as nuclear translocation of STAT6 and inhibition of STAT4 phosphorylation in PIBF-treated cells. The silencing of STAT6 by small interfering RNA reduced the cytokine effects. Because the activation of the STAT6 pathway depends on the ligation of IL-4R, we tested the involvement of IL-4R in PIBF-induced STAT6 activation. Although PIBF does not bind to IL-4R, the blocking of the latter with an Ab abolished PIBF-induced STAT6 activation, whereas the blocking of the IL-13R had no effect. PIBF activated suppressor of cytokine signaling-3 and inhibited IL-12-induced suppressor of cytokine signaling-1 activation. The blocking of IL-4R counteracted all the described effects, suggesting that the PIBF receptor interacts with IL-4R {alpha}-chain, allowing PIBF to activate the STAT6 pathway. PIBF did not phosphorylate Jak3, suggesting that the {gamma}-chain is not needed for PIBF signaling. Confocal microscopic analysis revealed a colocalization and at 37°C a cocapping of the FITC PIBF-activated PIBF receptor and PE anti-IL-4R-labeled IL-4R. After the digestion of the cells with phosphatidylinositol-specific phospholipase C, the STAT6-activating effect of PIBF was lost, whereas that of IL-4 remained unaltered. These data suggest the existence of a novel type of IL-4R composed of the IL-4R {alpha}-chain and the GPI-anchored PIBF receptor.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The progesterone-induced blocking factor (PIBF)3 is coded on locus 13q21-q22, which has been implicated as a common site for somatic deletions in a variety of malignant tumors (1), and the protein has been identified in undifferentiated cells and in malignancies (2). The molecule was initially discovered as a progesterone-induced protein (hence the name), mediating the immunological effects of progesterone (3). PIBF production is a characteristic feature of normal human pregnancy, whereas the lack of PIBF predicts spontaneous pregnancy termination (4). The neutralization of endogenous PIBF results in altered cytokine production and pregnancy termination in mice (5). PIBF induces a Th2-biased cytokine production in vitro (6) and in vivo (7).

STAT proteins were identified as transcription factors mediating virtually all cytokine driven signaling (8, 9, 10). STAT4 is needed for generation of Th1 cells (11), whereas STAT6-deficient mice fail to respond to IL-4, suggesting the importance of STAT6 in the activation of IL-4 inducible genes (10).

Suppressor of cytokine signaling (SOCS) proteins negatively regulate the signal transduction of several cytokines (12, 13, 14). SOCS-1 and SOCS-3 genes are induced by a variety of cytokines, IL-4 among others (15). CD4+ naive T cells constitutively express low levels of both SOCS-1 and SOCS-3 mRNA, and the differentiation into the Th1 or Th2 phenotype is accompanied by preferential expression of distinct SOCS mRNA transcripts and proteins (16).

IL-4R is a heterodimeric cytokine receptor system consisting of the signaling high-affinity {alpha}-chain and a transactivating low-affinity chain that can either be the common {gamma}-chain or the IL-13R {alpha}1-chain (17). The extracellular domain of the IL-4R {alpha}-chain provides nearly the complete ligand-binding affinity of the whole receptor (18). IL-4R {alpha}- and {gamma}-chains associate with the Janus kinases, Jak1 and Jak3, respectively (19). Ligand-induced heterodimerization of IL-4R {alpha}- and {gamma}-chains induces tyrosine phosphorylation of IL-4R{alpha} and activation of Jak1 and Jak3 (20). Phosphorylated tyrosine residues of IL-4R{alpha} serve as anchor for the Src homology 2 domain of STAT6, which gets phosphorylated (21) and forms homodimers. These translocate to the nucleus and bind to DNA sequences TTCNNN(N)GAA in the promoter region of IL-4 responsive genes (22).

PIBF exerts its biological effects by inducing a Th2-biased cytokine production, therefore, we investigated the effects of PIBF on the STAT6/STAT4 signaling pathways, and because activation of the STAT6 pathway is initiated through IL-4R, the possibility that PIBF signals via IL-4R was investigated.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Abs and PIBF

The 48-kDa N-terminal recombinant human PIBF was prepared as described earlier (3) and is referred to as PIBF throughout our report. Polyclonal anti-PIBF Abs were generated by immunizing rabbits with the 48-kDa N-terminal recombinant human PIBF. IgG was affinity purified on protein A columns.

Monoclonal anti-human IL-4R{alpha} as well as goat anti-human IL-13R{alpha}1 Abs (all from R&D Systems) were used for treating lymphocytes. Mouse IgG2A-specific Ig (Sigma-Aldrich), and rabbit IgG-specific and goat IgG-specific Abs (both from DakoCytomation) were used as isotype controls. Rabbit polyclonal phospho-specific (Tyr641) anti-human STAT6, phospho-specific (Tyr1022/Tyr1023) anti-human Jak1, phospho-specific (Tyr980) anti-human Jak3, anti-human SOCS-1, anti-human SOCS-3 Abs (all from Santa Cruz Biotechnology), rabbit polyclonal phospho-specific (Tyr693) anti-human STAT4 Ab (Zymed Laboratories), and HRP-labeled anti-rabbit IgG (DakoCytomation) were used for Western blotting. Polyclonal rabbit anti-human STAT6, anti-human Jak1, anti-human STAT4 Abs (all from Santa Cruz Biotechnology), and rabbit anti-human {beta}-actin (Sigma-Aldrich) were used for controlling the loading on Western blots. Polyclonal rabbit anti-human STAT6 Ab recommended for gel supershift studies (Santa Cruz Biotechnology) was used for EMSA supershift. Goat polyclonal anti-human IL-4 (R&D Systems), mouse monoclonal anti-human IL-4R{alpha}, HRP-labeled anti-goat IgG (both from DakoCytomation), streptavidin-biotin-HRP (Amersham Biosciences), and polyclonal biotin-conjugated anti-PIBF Abs (prepared in our laboratory) were used for ELISA. Mouse monoclonal anti-human IL-4R{alpha}, PE-labeled rat anti-mouse IgG2A and IgG2B (BD Biosciences), FITC-conjugated PIBF (prepared in our laboratory), PE-labeled mouse, anti-human CD45RA (BD Biosciences), and PE-labeled rat anti-mouse IgG1 (BD Biosciences) were used for immunofluorescence confocal microscopy. PIBF-FITC and mouse monoclonal anti-human IL-4R{alpha} Abs were used for determining the receptor binding of PIBF by flow cytometry.

Treatment of lymphocytes

Ficoll-Paque (Pharmacia) isolated PBL from healthy volunteers were washed in RPMI 1640 medium (Invitrogen Life Technologies), treated with 1 µg/ml PHA (Sigma-Aldrich) for 24 h, and then incubated at 37°C in 5% CO2 with the following: RPMI 1640 medium; 10, 20, and 200 ng/ml and 0.5, 1, and 10 µg/ml PIBF for 5 x 107 cells; PIBF, progesterone (Sigma-Aldrich) or recombinant human IL-4 (R&D Systems) for 1, 10, 20, and 30 min and 24 h; recombinant human IL-4 plus recombinant human IL-12 (both from R&D Systems), or rIL-4 plus rIL-12 plus monoclonal anti-IL-4R{alpha} Ab, or rIL-4 plus monoclonal anti-IL-4R{alpha} Ab; PIBF plus polyclonal anti-PIBF Ab, or PIBF plus monoclonal anti-IL-4R{alpha} Ab, or PIBF plus rIL-12 plus monoclonal anti-IL-4R{alpha} Ab, or PIBF plus rIL-12 plus monoclonal anti-IL-13R{alpha}1 Ab; rIL-12 plus PIBF or PIBF plus rIL-12 plus recombinant human IL-4; lysate of Escherichia coli that had undergone the same purification procedure as the recombinant human PIBF in a concentration of 200 ng/ml; and isotype controls used with each treatment.

The cytokines, PIBF, and progesterone were used at a concentration of 200 ng/ml for 5 x 107 cells, whereas anti-human IL-4R{alpha} and anti-human IL-13R{alpha}1 Abs were applied in a blocking concentration (50 µg/ml for 5 x 107 cells). All treatments were performed for 20 min.

Western blotting

Following treatment, lymphocytes were washed in PBS and then in PBS containing 1 mM sodium vanadate and 5 mM NaF. After centrifugation at 13,000 rpm for 40 s pellets were resuspended in 3x volumes of buffer containing 20 mM HEPES (pH 7.9), 20 mM NaF, 1 mM sodium vanadate, 1 mM Na4P2O7, 1 mM EDTA, 1 mM EGTA, 5 mM DTT, 0.5 mM PMSF, aprotinin (0.01 µg/ml), leupeptin (0.025 µg/ml), 400 mM NaCl, and 20% glycerol. Samples were frozen and thawed three times and kept on ice for a further 20 min. After centrifugation at 15,000 rpm at 4°C for 30 min, supernatants were collected, and the protein content of the extracts was determined. The 25 µg of total protein was separated on 7.5 or 12% SDS-PAGE and transferred to a Hybond ECL membrane (Amersham Biosciences) overnight at 54 mA. The blots were blocked with 3% nonfat dry milk in TBS-Tween solution for 60 min, then incubated with 1/20,000 diluted phospho-specific anti-STAT6 or with 3 µg/ml phospho-specific anti-STAT4, 1/2000 diluted phospho-specific anti-Jak1, 1/200 diluted phospho-specific anti-Jak3, or with 1/200 diluted anti-SOCS-1, or with 1/200 diluted anti-SOCS-3 Abs in TBS-Tween solution containing 3% nonfat dry milk for 1 h. For controlling the loading, 1/1000 diluted anti-STAT6, 1/1000 diluted anti-STAT4, 1/1000 diluted anti-Jak1 Abs, or 1/1000 diluted anti-{beta}-actin Abs was used. After six washing cycles (10 min each) in TBS-Tween (pH 7.4), the blots were incubated at room temperature for 45 min with 1/2000 diluted HRP-labeled anti-rabbit IgG, and then washed six times (10 min each) in TBS-Tween. Ab binding was detected using an ECL kit (PerkinElmer) according to the manufacturer’s instructions.

EMSA supershift

Nuclear extracts were prepared as described by Xu and Cooper (23). Lymphocytes were washed twice in ice-cold PBS and resuspended in 10 volumes of buffer containing 10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, protease inhibitors (complete, Mini EDTA-free tablets; Boehringer Mannheim), phosphatase inhibitors (Phosphatase Inhibitor Cocktail; Sigma-Aldrich) and placed on ice for 10 min. After vigorous vortexing, nuclei were collected by centrifugation in microcentrifuge at 10,000 rpm for 10 s, resuspended in 2 volumes of buffer containing 20 mM HEPES (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, protease inhibitors, and phosphatase inhibitors and incubated on ice for 20 min. After centrifugation (10,000 rpm for 10 s) supernatants were collected and the protein content of the extracts was determined, aliquoted, and stored at –80°C. For the shift assay, STAT6 binding probes (5'-TCGACTTCCCAAGAACAGCA-3') and their reverse complementary pairs were incubated at 80°C for 10 min in annealing buffer containing 100 mM NaCl, 10 mM Tris (pH 7.5), 1 mM EDTA and allowed to cool down slowly to room temperature. Double-stranded oligonucleotides were end-labeled with [{gamma}-32P]ATP using T4 polynucleotide kinase (Promega) according to the manufacturer’s protocol. Binding was performed at room temperature for 30 min in 20 µl volume, containing 300 ng of poly(deoxyinosinic-deoxycytidylic acid), 100 mM NaCl, 0.25 mM EDTA, 1 mM DTT, 20 mM HEPES (pH 7.9), and 20 fmol 32P-labeled oligonucleotide probe. For supershift assays the reaction mixtures were preincubated with 1 µl of rabbit anti-human STAT6 IgG (2 µg/µl) for 1 h at 4°C before adding the 32P-labeled oligonucleotide. Samples were separated on 3.5% acrylamide gel with 0.5x Tris-borate-EDTA buffer. The gel was dried and exposed to x-ray film.

Phosphatidylinositol-specific phospholipase C (PI-PLC) treatment

A total of 5 x 106 PHA treated lymphocytes was incubated with 2.5 U of PI-PLC (Sigma-Aldrich) in 1 ml of PBS for 30 min at 37°C in 5% CO2, and washed twice with PBS.

ELISA for detecting PIBF binding to IL-4R

During an overnight incubation at 4°C, 96-well microtiter plates were coated with 1 and 0.5 µg/ml soluble recombinant human IL-4R{alpha} (R&D Systems) in 50 mM carbonate buffer (pH 9.6). All further incubations were performed at 37°C. Plates were washed three times and free binding sites were blocked with PBS containing 0.05% Tween, 0.5% gelatin, and 0.1% BSA for 60 min. Logarithmic dilutions (0.01–1 µg/ml) of PIBF or rIL-4 in PBS Tween (pH 7.4) were incubated on the plates for 60 min. The plates were washed three times and incubated with 1/1000 diluted biotin-conjugated anti-PIBF IgG or 1/1000 diluted goat anti-IL-4 for 60 min. Following three further washing cycles, biotin-conjugated anti-PIBF IgG was reacted with 1/1000 diluted streptavidin-biotin-HRP for 30 min, while anti-IL-4 Ab was reacted with 1/2000 diluted HRP-labeled anti-goat IgG for 60 min. The reaction was developed with O-phenylenediamine (FLUKA; Sigma-Aldrich) and stopped by adding 50 µl of 4 M H2SO4. Absorbance was read at 490 nm.

Determination of receptor binding of PIBF by flow cytometry

One million PBL from healthy volunteers were incubated with 2 µg/ml FITC-conjugated PIBF in the presence of increasing concentrations (0–200 µg/ml) of unlabeled PIBF or monoclonal anti-IL-4R{alpha} Ab for 30 min at 4°C. The cells were washed in PBS, fixed in 0.5 ml 4% PBS-formalin, and analyzed by flow cytometry, using a FACSCalibur flow cytometer equipped with a 488-nm excitation laser with the CellQuest software program (both from BD Biosciences).

Confocal microscopy

One million PBL from healthy volunteers were incubated with 5 µg of FITC-conjugated PIBF for 20 min at 37°C. A total of 1 x 105 cells was plated on poly-L-lysine-coated slides and incubated at 37°C for further 10 min, then washed twice in PBS containing 1% FCS and fixed with freshly prepared 3% paraformaldehyde in PBS for 10 min at room temperature. After washing, the plates were incubated with 0.5 µg of monoclonal anti-IL-4R{alpha} or 2 µl of PE-labeled mouse anti-CD45RA Ab for 45 min at room temperature. Cells were washed twice and incubated with 2 µl of PE-labeled rat anti-mouse IgG2A and IgG2B or PE-labeled rat anti-mouse IgG1 for 30 min at room temperature. Cells were washed twice and the slides were mounted with DABCO (Sigma-Aldrich). To control the specificity of capping formation, all steps were also performed at 4°C. The slides were analyzed with a Bio-Rad confocal microscope with x100 objective, using laser excitation at 473 nm with filters 580 ± 16 nm for PE and 522 ± 17.5 nm for FITC. Images were analyzed using the Adobe Photoshop 7.0 software.

RNA interference

Oligonucleotides were hand-designed to interfere exclusively with STAT6 mRNA (Ambion). As a negative control, the same nucleotides were scrambled to form a nongenomic combination (controlled by basic local alignment search tool). Oligonucleotide sequences used for STAT6 RNA interference were target sequence for STAT6 AAG CAG GAA GAA CTC AAG TTT and target sequence scrambled AAA CGA GAG TGT TAT AAC TGT.

Cells were washed twice with OptiMEM (Invitrogen Life Technologies). Oligonucleotides were dissolved in RNase-free water, annealed according to the guidelines provided by the manufacturer, and incubated for 20 min at room temperature with Oligofectamine (Invitrogen Life Technologies). This mixture was added dropwise to the cells, until a concentration of 66 nM was reached. After 4 h incubation at 37°C, DMEM containing 30% FCS was added to cultures. Western blots for STAT6 expression were performed 24 h subsequent to small interfering (si)RNA transfection. STAT6 expression was markedly reduced, whereas STAT2 and STAT4 expressions were not affected (see Fig. 2A).



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 2. STAT6 is required for the cytokine effects of PIBF. The effect of PIBF on cytokine production by STAT6-deficient (siRNA) lymphocytes. Intact lymphocytes, those treated with scrambled oligonucleotides, and those after RNA interference were adjusted to 106 cells/ml in RPMI 1640 with 10% FCS and cultured for 48 h at 37°C, 5% CO2 in a humidified atmosphere together with 0.2 or 10 µg/ml PIBF, or without PIBF. Cytokines were determined from the supernatants by cytometric bead array. Lymphocytes were lysed for Western blot analysis. Controls include intact lymphocytes (–) and those treated with nongenomic sequence oligonucleotides (SCR). E. coli lysate controls were included to rule out the effect of LPS contamination on cytokine production. These had no effect on IL-10 and IFN-{gamma} production, although they induced a slightly increased TNF-{alpha} production. The data shown are corrected for E. coli lysate control. Data are the mean ± SEM of nine individual experiments. Significantly different (*, p < 0.05) values from controls are shown. A, The efficiency and specificity of STAT6 depletion by siRNA. Western blots of lysates from siRNA-treated cells were reacted with anti-STAT6, anti-STAT4, or anti-STAT2. A representative experiment is shown. B, The effect of PIBF on IL-10 production. C, The effect of PIBF on TNF-{alpha} production. D, The effect of PIBF on IFN-{gamma} production.

 
Lymphocyte cultures

Intact lymphocytes, those treated with scrambled oligonucleotides and those after RNA interference were adjusted to 106 cells/ml in RPMI 1640 with 10% FCS, and cultured for 48 h at 37°C, 5% CO2 in a humidified atmosphere together with 0.2 or 10 µg/ml PIBF or without PIBF. Supernatants were harvested for cytokine determination. Lymphocytes were lysed for Western blot analysis.

Cytometric bead arrays

IL-10, TNF-{alpha}, and IFN-{gamma} concentrations were determined by Cytometric Bead Array (CBA; BD Biosciences or Bender MedSystems). Supernatants were incubated with labeled capture beads and detection reagent for 3 h in the dark at room temperature, and analyzed with flow cytometer (FACSCalibur; BD Biosciences for BD arrays or alternatively Galaxy; DakoCytomation) by using the respective CBA Analysis software (BD Biosciences) and Bender MedSystems software.

Statistical analysis

The two-tailed Student’s t test was used for statistical evaluation of the data. Differences were considered significant if the value for p ≤ 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
PIBF activates STAT6

To test whether the previously described cytokine effects of PIBF were mediated by the Jak/STAT pathway, cytoplasmic fractions of PIBF-treated or untreated human PBL were separated on SDS-PAGE, blotted to nitrocellulose membranes, and reacted with anti-phospho-STAT6 Abs. Controls included the lysate of E. coli that had undergone the same purification procedure as the recombinant PIBF, as well as isotype controls. Similar to IL-4, PIBF induced STAT6 phosphorylation, which was inhibited by a neutralizing anti-PIBF IgG (Fig. 1A). To clarify whether PIBF induces nuclear translocation of phosphorylated STAT6 dimers, nuclear extracts prepared from PIBF-treated cells, and those from IL-4-treated as well as untreated lymphocytes were hybridized with labeled STAT6 binding, specific oligonucleotide probes and their reverse complementary pairs. PIBF induced nuclear translocation of STAT6 in lymphocytes. The specificity of the reaction was verified with a supershift assay. This result is based on anti-STAT6 IgG-STAT6 forming high molecular mass complexes, which migrate slower than STAT6 alone.



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 1. PIBF activates STAT6. A, PIBF treatment induces STAT6 phosphorylation. Cytoplasmic fractions of untreated human PBL, and those treated for 20 min with PIBF or PIBF plus anti-PIBF IgG, were separated on SDS-PAGE, blotted to nitrocellulose membrane, and reacted with anti-phospho-STAT6 Abs. B, PIBF treatment induces nuclear translocation of STAT6. Nuclear extracts from untreated human PBL, and those treated for 20 min with PIBF or IL-4 were hybridized with radioactive labeled STAT6 binding specific oligonucleotide probes 5'-TCGACTTCCCAAGAACAGCA-3' and their reverse complementary pairs. The samples were separated by nondenaturing PAGE and the bands were detected by autoradiography. Supershift was performed with anti-STAT6 Ab. C, Time-dependence of STAT6 phosphorylation. STAT6 phosphorylation was tested on lysates of lymphocytes incubated with 200 ng/ml PIBF (b), IL-4 (a), or progesterone (c) for varying periods. D, Concentration dependence of STAT6 activation by PIBF. STAT6 phosphorylation was tested on lysates of lymphocytes incubated for 20 min with different concentrations of PIBF. Western blots were reacted with anti-phospho-STAT6 (top) or anti-STAT6 Ab (bottom).

 
In the presence of anti-STAT6 IgG, a supershifted complex appeared in the extract of PIBF-treated lymphocytes. This band was not detectable when the irrelevant anti-NF-{kappa}B Ab was used (Fig. 1B).

To investigate the concentration- and time-dependence of PIBF effects, STAT6 phosphorylation was tested on lysates of lymphocytes incubated with different concentrations of PIBF or with 200 ng/ml PIBF for varying periods. Tyrosine phosphorylated STAT6 appeared as early as 1 min after addition of IL-4 (Fig. 1C, a) or PIBF (Fig. 1C, b) to the cells, whereas a 24-h continuous presence of progesterone was required for the same effect (Fig. 1C, c). PIBF in concentrations from 10 ng to 10 µg/ml exerted a concentration-dependent effect on STAT6 phosphorylation (Fig. 1D). Our earlier data show that during normal pregnancy PIBF concentrations in urine reach 100–300 ng/ml, serum PIBF levels of the same women being usually higher. In patients with malignant tumors, PIBF levels are more variable (100–1000 ng/ml in urine). Based on these data, we chose 200 ng/ml for further treatments as a concentration relevant to in vivo biological situations.

STAT6-mediated signal transduction is involved in the cytokine effects of PIBF

To verify the involvement of the STAT6 pathway in the cytokine effects of PIBF, STAT6 was silenced in PBL with oligonucleotides interfering with STAT6 mRNA (siRNA). Cells treated with the same nucleotides in a scrambled, nongenomic order served as controls. The efficiency and specificity of STAT6 depletion was checked by reacting the lysates of siRNA-treated cells with anti-STAT6 or anti-STAT4 and anti-STAT2 Abs. Although the efficiency of STAT6 depletion was variable, silencing was in all cases specific for STAT6. A representative experiment is shown in Fig. 2A. STAT6 knocked down, as well as control lymphocytes, were incubated with PIBF for 48 h, and IL-10, IFN-{gamma}, as well as TNF-{alpha} concentrations of the culture medium, were determined with a cytometric bead assay. For controlling the effect of possible LPS contamination in recombinant PIBF, parallel lymphocyte samples were treated with lysates of E. coli that had undergone the same purification procedure as the recombinant PIBF.

Compared with the controls, the concentrations of both TNF-{alpha} (Fig. 2C) and IFN-{gamma} (Fig. 2D) were significantly increased in STAT6-deficient cells treated with 10 µg/ml PIBF. PIBF increased IL-10 production of intact lymphocytes in a concentration-dependent manner. Similar changes were observed in cells treated with nongenomic sequence oligonucleotides and in STAT6-deficient cells. In the latter group, PIBF-induced elevation of IL-10 production was lower compared with scrambled (SCR) control; however the difference was not statistically significant (Fig. 2B). A pitfall of the RNA interference method is that according to recent findings, nonspecific effects that include both the up-regulation and suppression of nontargeted genes can be observed (24), which could account for elevated IL-10 levels in supernatants of cells treated with the nongenomic sequence. Therefore SCR control might be more appropriate as a baseline than untreated cells.

PIBF-induced activation of the STAT6 pathway is mediated by IL-4R

STAT6 signaling is initiated by the engagement of IL-4R. Assuming that PIBF might be a ligand of IL-4R, the STAT6 activating effect of PIBF was tested in lymphocytes pretreated with blocking concentrations of anti-IL-4R or anti-IL-13R Ab. The blocking of the IL-13R had no effect, but the use of a blocking anti-IL-4R mAb counteracted PIBF-induced STAT6 activation (Fig. 3A). This was, however, not due to the inhibition of the binding of PIBF to IL-4R because we could not demonstrate PIBF binding to IL-4R by ELISA (Fig. 3B), nor did anti-IL-4R treatment prevent PIBF binding to its own receptor (Fig. 3C). STAT6 phosphorylation by PIBF was not affected by simultaneous anti-IL-4 treatment (Fig. 3D).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 3. PIBF-induced STAT6 activation is mediated by IL-4R. A, The effect of IL-4R block on PIBF-induced STAT6 phosphorylation. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF, PIBF and anti-IL-4R{alpha}, or PIBF and anti-IL-13R Ab, are reacted with anti-phospho-STAT6 (top) or anti-STAT6 (bottom) Ab. B, Binding PIBF to IL-4R ELISA plates coated with IL-4R{alpha} were reacted with increasing concentrations of PIBF or IL-4, and subsequently with anti-PIBF and anti-IL-4 Abs, respectively. A representative experiment is shown. C, The blocking of IL-4R does not inhibit PIBF binding to its receptor. Lymphocytes were incubated with 2 µg/ml FITC-labeled PIBF in the presence of increasing concentrations of unlabeled PIBF or anti-IL-4R Ab. The percentage of FITC PIBF binding cells was determined by flow cytometry. A representative experiment is shown. D, The effect of anti-IL-4 does not affect PIBF-induced STAT6 phosphorylation. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF, PIBF and anti-IL-4, IL-4, IL-4 plus anti-IL-4, or anti-IL-4 alone are reacted with anti-phospho-STAT6 (top) or anti-STAT6 (bottom) Ab.

 
PIBF induces phosphorylation of the IL-4R{alpha}-associated Jak1 (Fig. 4A), but not that of the {gamma}-chain-associated Jak3 (Fig. 4B), and the former effect is inhibited by anti-IL-4R Ab (Fig. 4A).



View larger version (9K):
[in this window]
[in a new window]
  		FIGURE 4. PIBF phosphorylates Jak1, but not Jak3. A, The effect of PIBF treatment and IL-4R blocking on phosphorylation of Jak1. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF, IL-4, or PIBF and anti-IL-4R{alpha} Ab cells, are reacted with anti-phospho-Jak1 (top) or anti-Jak1 (bottom) Ab. B, The effect of PIBF treatment on phosphorylation of Jak3. Lysates of untreated human lymphocytes, and those treated for 20 min with IL-4 or PIBF, are reacted with anti-phospho-Jak3 (top) or anti-{beta}-actin (bottom) Ab.

 
Both PIBF and IL-4 treatment resulted in activation of SOCS-3, and blocking of IL-4R abolished the effect (Fig. 5A). IL-12-induced SOCS-1 activation was inhibited by PIBF, and the latter effect was abolished by blocking IL-4R (Fig. 5B). SOCS-3 inhibits IL-12 signaling, which explains the finding that IL-12-induced STAT4 phosphorylation disappeared after PIBF treatment in the absence, but not in the presence of anti-IL-4R{alpha} Ab (Fig. 5C). Treatment of the cells with anti-IL-12 Ab inhibited STAT4 phosphorylation, suggesting that the freshly isolated PBL were under IL-12 effect (Fig. 5D).



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 5. PIBF induces SOCS-3 and inhibits SOCS-1 induction as well as STAT4 phosphorylation via IL-4R{alpha}. A, The effect of PIBF and anti-IL-4R{alpha} Ab on SOCS-3 induction. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF, IL-4, PIBF and anti-IL-4R{alpha}, IL-4 and anti-IL-4R{alpha}, or IL-12, are reacted with anti-SOCS-3 (top) or anti-{beta}-actin (bottom) Ab. B, The effect of PIBF and anti-IL-4R{alpha} Ab on IL-12-induced SOCS-1 induction. Lysates of untreated human lymphocytes, and those treated for 20 min with IL-12, IL-12 and PIBF, IL-12 and IL-4, IL-12 and PIBF and anti-IL-4R{alpha}, IL-12 and PIBF and anti-IL-13R, or IL-12 and IL-4 and anti-IL-4R{alpha} Ab are reacted with anti-SOCS-1 (top) or anti-{beta}-actin (bottom) Ab. C, The effect of PIBF and anti-IL-4R{alpha} Ab on STAT4 phosphorylation. Lysates of untreated human lymphocytes, and those treated for 20 min with PIBF, IL-12, IL-12 and PIBF, IL-12 and PIBF and anti-IL-4R{alpha}, or anti-IL-4R{alpha} Ab, are reacted with anti-phospho-STAT4 (top) or anti-STAT4 (bottom) Ab. D, The effect of anti-IL-12 Ab treatment on STAT4 phosphorylation in freshly isolated PBL. Lysates of untreated human PBL, and those treated for 20 min with anti-IL-12 or IL-12, are reacted with anti-phospho-STAT4 (top) or anti-STAT4 (bottom) Ab.

 
Functional association of PIBF receptor and IL-4R with PIBF receptor as a GPI-anchored protein

Our data suggest that the PIBF receptor might form a heterodimer with IL-4R{alpha} to activate the STAT6 pathway. Confocal microscopy analysis of PE anti-IL-4R{alpha} and FITC PIBF-labeled cells revealed a cocapping of the two receptors, when PIBF labeling was done at 37°C (Fig. 6A, top panel), whereas PE anti-CD45 and FITC-PIBF did not colocalize (data not shown). Six cocapping experiments on PBL from different healthy individuals under the same conditions gave similar results. Typically cocapping was observed on 18% of the cells, and 1.7% of lymphocytes reacted with IL-4R-PE only, whereas the ratio of single FITC PIBF-positive cells was negligible.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 6. The PIBF receptor is a GPI-anchored protein and forms a heterodimer with IL-4R{alpha}. A, Colocalization at 4°C (bottom) and cocapping at 37°C (top) of IL-4R{alpha} and PIBF receptor. View of FITC PIBF (a), PE anti-IL-4R{alpha} (b), and merged (c) are presented. For capping (top), lymphocytes were incubated with FITC-conjugated PIBF for 30 min at 37°C, fixed and reacted with monoclonal anti-IL-4R{alpha} for 45 min at room temperature, followed by incubation with PE-labeled rat anti-mouse IgG2A and IgG2B or PE-labeled rat anti-mouse IgG1 for 30 min at room temperature. Fluorescence and transmission views are merged to show the cellular localization of the receptors. B, PI-PLC treatment results in a loss of STAT6 activation by PIBF. Cell lysates of PI-PLC digested PIBF, IL-4-treated and control untreated (marked as 0) as well as nondigested cells are reacted with anti-phospho-STAT6 (top) or anti-STAT6 (bottom) Ab.

 
No capping was seen in cells incubated at 4°C with the Abs (Fig. 6A, bottom panel).

Because IL-4R{alpha} was a requirement for PIBF signaling, we tested whether PIBF receptor was a GPI-anchored protein. Digesting the putative anchoring region with PI-PLC resulted in a loss of STAT6 activation by PIBF, whereas the same effect of IL-4 remained unaltered (Fig. 6B).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In this study we suggest the existence of a new type of IL-4R, in which the {alpha}-chain of the IL-4R is complemented by the GPI-anchored PIBF receptor. The treatment of human PBL with low concentrations of PIBF results in immediate phosphorylation and nuclear translocation of STAT6. STAT6 activation is dependent on ligation of IL-4R (21). This implies that for activating STAT6, PIBF needs to interact with IL-4R. Indeed, the STAT6 activating effect of PIBF was lost after blocking the IL-4R {alpha}-chain by a specific Ab. In contrast, we could not demonstrate a direct binding of PIBF to IL-4R{alpha}, nor could we prevent PIBF from binding to its own receptor by anti-IL-4R treatment. The possibility that the PIBF Ab binds to a region within PIBF that is required for interaction with the IL-4R, thus competing for the same site on PIBF, can be ruled out because in the ELISA we used a polyclonal anti-PIBF IgG, which recognizes multiple epitopes on the PIBF molecule. Furthermore, the assay performed in a reverse order (solid phase bound PIBF reacted with IL-4R{alpha}, revealed with anti-IL-4R{alpha}) gave similarly negative results. Previously we showed (6) that supernatants from spleen cells activated in the presence of PIBF produce significantly more IL-4 than those in the absence of PIBF. The possible scenario in which instead of PIBF, PIBF-induced IL-4 would bind to the IL-4R and phosphorylate STAT6, can also be excluded. As short as a 1 min incubation with PIBF is sufficient to induce the phosphorylation of STAT6. This is too short an interval for gene induction plus the synthesis of IL-4. Another argument against this concept is that treatment of the cells with anti-IL-4 Abs did not inhibit, nor even reduce the effect of PIBF on STAT6 phosphorylation.

The blocking of the IL-13R (which consists of an IL-13 binding IL-13R {alpha}-chain (25, 26) and IL-4R{alpha}) (27) does not exert a similar effect, suggesting that the IL-4R {alpha}-chain is needed for the STAT6-inducing effect of PIBF.

Because PIBF does not directly bind to IL-4R, but STAT6 phosphorylation is inhibited by anti-IL-4R Ab, we investigated the effect of IL-4R block on Jak phosphorylation in PIBF-treated cells. PIBF-induced Jak1 phosphorylation was inhibited by anti-IL-4R Ab treatment, whereas the blocking of IL-13R had no effect.

STAT4 was phosphorylated in untreated cells, and this did not change upon addition of IL-12. In this study we used freshly isolated lymphocytes from healthy individuals, which produce IL-12. The treatment of the cells with anti-IL-12 Ab abolished STAT4 phosphorylation, thus phosphorylation of STAT4 in untreated lymphocytes could be due to IL-12 already present in the system. The STAT4 activating effect of IL-12 was counteracted by PIBF in the absence, but not in the presence of anti-IL-4R Ab. This implies that effects of PIBF (both the positive ones on STAT6 and the negative ones on STAT4) are dependent on the IL-4R {alpha}-chain.

Ligand binding of IL-4R leads to phosphorylation of Jak1. Jak then phosphorylates STATs, which move into the nucleus and activate the transcription of, among others, genes coding for the SOCS proteins. IL-12/STAT4 and IL-4/STAT6 pathways are under negative feedback regulation by SOCS proteins. SOCS-3 is induced by IL-4 signal, then it binds to IL-12R and inhibits IL-12 signaling (28). Thus, IL-12-induced STAT4 activation is inhibited in Th2 cells that express high levels of SOCS-3, whereas IL-4/STAT6 signaling is constitutively activated in Th2 cells, but not in Th1 cells, with high SOCS-1 expression (16). In our hands, similar to IL-4, PIBF treatment induced SOCS-3 activation, whereas the IL-12-induced SOCS-1 expression disappeared after PIBF or IL-4 treatment. All of the described effects were abolished by the IL-4R block.

Based on the currently available data, STAT6 signaling is initiated by IL-4 or IL-13 binding to IL-4R (29). Although we could not demonstrate direct binding of PIBF to IL-4R{alpha}, blocking of the latter suspended all IL-4R-dependent effects of PIBF. Furthermore, with confocal microscopy we demonstrated not only colocalization, but under appropriate conditions, also cocapping of IL-4R{alpha} and the PIBF receptor. Therefore the hypothesis was put forward that, following ligation, the PIBF receptor might either form a heterodimer with the {alpha}-chain of the IL-4R, or the engaged PIBF receptor associates with the complete IL-4R, allowing PIBF to activate the STAT6 pathway. To date because of the lack of a PIBF receptor-specific Ab, coprecipitation of the two receptors has not been performed. However, the finding that PIBF treatment induces the phosphorylation of Jak1 (associated with the IL-4R {alpha}-chain), but not that of Jak3, which is associated with the {alpha}-chain, provides strong indirect evidence for the former and against the latter concept.

Our findings raise the question, why IL-4R{alpha} is needed for PIBF signaling. A plausible explanation would be that the PIBF receptor itself does not possess an intracellular domain; therefore it uses that of IL-4R{alpha}. Several proteins are anchored to membranes via a posttranslational lipid modification, the GPI anchor. Ligation of these proteins by Abs results in signal transduction, despite the fact that these molecules have no transmembrane or intracellular domains. Their signaling capacity is due to the association of these molecules with putative transmembrane proteins that can signal via conventional mechanisms (30).

Testing the hypothesis that the PIBF receptor was a GPI-anchored protein, we digested the anchoring region with PI-PLC. After this treatment, IL-4 was still able to activate STAT6, but PIBF failed to do so, suggesting that a GPI-anchored protein was involved in PIBF signaling. GPI deficiency causes female infertility in mice (31), but to date the protein needed for maintaining pregnancy has not been identified. PIBF deficiency ablates murine pregnancy (5), suggesting that the PIBF receptor might be considered a candidate. These findings would explain not only the pregnancy protective (5), but also the cytokine-promoting (6) and possible tumor-promoting (2) effects of PIBF.

The concept that both IL-4R{alpha} and PIBF receptor are required for PIBF signaling is supported by the following: 1) anti-IL-4R{alpha} does not prevent binding of PIBF to its receptor, suggesting that PIBF receptor and IL-4R{alpha} are separate entities; 2) digesting the GPI anchor abolishes PIBF-driven signaling, thus a GPI-anchored protein is required for PIBF signaling; and 3) anti-IL-4R{alpha} Ab inhibits PIBF-induced STAT6 phosphorylation in intact cells showing that PIBF cannot signal via its own receptor without the involvement of IL-4R{alpha}. Taken together, the GPI-anchored PIBF receptor is required, but not sufficient, for PIBF signaling.

Our data suggest the existence of a novel IL-4R (Fig. 7A) in which upon ligation, the PIBF receptor combines with IL-4R{alpha} (Fig. 7B) and induces Jak1 phosphorylation, which in turn, activates STAT6. In STAT6-deficient cells, both the Th2 cytokine-inducing and Th1 cytokine-inhibiting effects of PIBF were reduced. PIBF-induced SOCS-3, through binding to the IL-12R, inhibits STAT4 phosphorylation (Fig. 7C) and Th1 responses.



View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 7. PIBF acts on the cytokine balance via a novel type of IL-4R. A, In addition to the classical IL-4R, in which IL-4R {alpha}-chain dimerizes with the common {gamma}-chain (1) or the {alpha}-chain (2) of the IL-13R, IL-4R {alpha}-chain forms a heterocomplex with the PIBF receptor (3). B, Upon ligation, the PIBF receptor associates with IL-4R{alpha}. C, PIBF binding to the PIBF receptor-IL-4R{alpha} complex results in Jak1 phosphorylation, which in turn activates STAT6. STAT6 dimers move to the nucleus, where they activate a number of genes. PIBF-induced SOCS-3 binds to IL-12R and inhibits STAT4 phosphorylation.

 

   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by Grant OTKA T031737 from the Hungarian National Research Fund, Grant ETT 045/2003 from the Hungarian Ministry of Health, Grant NKFP 1A-057-2004 from the National Research and Development Program, Grant GVOP-3.1.1.-2004-05-0329/3.0 from the Economic Competitiveness Operative Program, and by the Hungarian Academy of Sciences. Most authors are members of a European Network of Excellence on Embryo Implantation Control supported by the European Commission. This paper is Contract No. 512040. Back

2 Address correspondence and reprint requests to Dr. Julia Szekeres-Bartho, Department of Medical Microbiology and Immunology, Pecs University, Medical School, 12 Szigeti Strasse, H-7624 Pecs, Hungary. E-mail address: szjuli{at}main.pote.hu Back

3 Abbreviations used in this paper: PIBF, progesterone-induced blocking factor; SOCS, suppressor of cytokine signaling; PI-PLC, phosphatidylinositol-specific phospholipase C; siRNA, small interfering RNA; SCR, scrambled. Back

Received for publication July 14, 2005. Accepted for publication November 2, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Rozenblum, E., P. Vahteristo, T. Sandberg, J. T. Bergthorsson, K. SyrJakoski, D. Weaver, K. Haraldsson, H. K. Johannsdottir, P. Vehmanen, S. Nigam, et al 2002. A genomic map of a 6-Mb region at 13q21–q22 implicated in cancer development: identification and characterization of candidate genes. Hum. Genet. 110: 111-121. [Medline]
  2. Lachmann, M., D. Gelbmann, E. Kálmán, B. Polgár, M. Buschle, A. Von Gabain, J. Szekeres-Barthó, E. Nagy. 2004. PIBF (progesterone-induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int. J. Cancer 112: 51-60. [Medline]
  3. Polgár, B., G. Kispal, M. Lachmann, C. Paar, E. Nagy, P. Csere, E. Mikó, L. Szereday, P. Varga, J. Szekeres-Barthó. 2003. Molecular cloning and immunological characterization of a novel cDNA coding for PIBF. J. Immunol. 171: 5956-5963. [Abstract/Free Full Text]
  4. Polgár, B., E. Nagy, E. Mikó, P. Varga, J. Szekeres-Barthó. 2004. Urinary PIBF (progesterone-induced blocking factor) concentration is related to pregnancy outcome. Biol. Reprod. 5: 1699-1705.
  5. Szekeres-Barthó, J., G. Par, L. Szereday, C. Y. Smart, I. Achacz. 1997. Progesterone and non-specific immunological mechanisms in pregnancy. Am. J. Reprod. Immunol. 38: 176-182.
  6. Szekeres-Barthó, J., T. G. Wegmann. 1996. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J. Reprod. Immunol. 31: 81-95. [Medline]
  7. Szereday, L., P. Varga, J. Szekeres-Barthó. 1997. Cytokine production in pregnancy. Am. J. Reprod. Immunol. 38: 418-422.
  8. Hoey, T., M. J. Grusby. 1999. STATs as mediators of cytokine-induced responses. Adv. Immunol. 71: 145-162. [Medline]
  9. Kaplan, M. H., Y. L. Sun, T. Hoey, M. J. Grusby. 1996. Impaired IL-12 responses and enhanced development of Th2 cells in STAT4-deficient mice. Nature 382: 174-177. [Medline]
  10. Kaplan, M. H., U. Schindler, S. T. Smiley, M. J. Grusby. 1996. STAT6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4: 313-319. [Medline]
  11. Thierfelder, W. E., J. M. van Deursen, K. Yamamoto, R. A. Tripp, S. R. Sarawar, R. T. Carson, M. Y. Sangster, D. A. Vignali, P. C. Doherty, G. C. Grosveld, J. N. Ihle. 1996. Requirement for STAT4 in IL-12 mediated and responses of natural killer and T cells. Nature 382: 171-174. [Medline]
  12. Haque, S. J., P. Harbor, M. Tabrizi, T. Yi, B. R. Williams. 1998. Protein-tyrosine phosphatase Shp-1 is a negative regulator of IL-4 and IL-13-dependent signal transduction. J. Biol. Chem. 273: 33893-33896. [Abstract/Free Full Text]
  13. Hanson, E. M., H. Dickensheets, C. K. Qu, R. P. Donnelly, A. D. Keegan. 2003. Regulation of the dephosphorylation of Stat6: participation of Tyr-713 in the interleukin-4 receptor {alpha}, the tyrosine phosphatase SHP-1, and the proteasome. J. Biol. Chem. 278: 3903-3911. [Abstract/Free Full Text]
  14. Dickensheets, H. L., C. Venkataraman, U. Schindler, R. P. Donnelly. 1999. Interferons inhibit activation of STAT6 by interleukin-4 in human monocytes by inducing SOCS-1 gene expression. Proc. Natl. Acad. Sci. USA 96: 10800-10805. [Abstract/Free Full Text]
  15. Aman, M. J., W. J. Leonard. 1997. Cytokine signaling:cytokine-inducible signaling inhibitors. Curr. Biol. 7: R784-R788. [Medline]
  16. Egwuagu, C. E., C. R. Yu, M. Zhang, R. M. Mahdi, S. J. Kim, I. Gery. 2002. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells: implications for Th cell lineage commitment and maintenance. J. Immunol. 168: 3181-3187. [Abstract/Free Full Text]
  17. Reinemer, P., W. Sebald, A. Duschl. 2000. The interleukin-4-receptor: from recognition mechanism to pharmacological target structure. Angew. Chem. Int. Ed. Engl. 39: 2834-2846. [Medline]
  18. Shen, B. J., T. Hage, W. Sebald. 1996. Global and local determinants for the kinetics of interleukin-4/interleukin-4 receptor {alpha} chain interaction: a biosensor study employing recombinant interleukin-4-binding protein. Eur. J. Biochem. 240: 252-261. [Medline]
  19. Miyazaki, T., A. Kawahara, H. Fujii, Y. Nakagawa, Y. Minami, J. Z. Liu, I. Oishi, O. Silvennoinen, B. A. Witthuhn, J. N. Ihle, T. Taniguchi. 1994. Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science 266: 1045-1047. [Abstract/Free Full Text]
  20. Leonard, W. J., J. J. O’Shea. 1998. Jaks and STATs: biological implications. Annu. Rev. Immunol. 16: 293-322. [Medline]
  21. Hou, J., U. Schindler, W. J. Henzel, T. C. Ho, M. Brasseur, S. L. McKnight. 1994. An interleukin-4-induced transcription factor: IL-4 Stat. Science 265: 1707-1706.
  22. Fenghao, X., A. Saxon, A. Nguyen, Z. Ke, D. Diaz-Sanchez, A. Nel. 1995. Interleukin 4 activates a signal transducer and activator of transcription (Stat) protein which interacts with an interferon-{gamma} activation site-like sequence upstream of the I{epsilon} exon in a human B cell line: evidence for the involvement of Janus kinase 3 and interleukin-4 Stat. J. Clin. Invest. 96: 907-914. [Medline]
  23. Xu, W., M. G. Cooper. 1995. Identification of a candidate c-mos repressor that restricts transcription of germ cell specific genes. Mol. Cell. Biol. 15: 5369-5375. [Abstract]
  24. Sledz, C. A., B. R. G. Williams. 2004. RNA interference and double-stranded-RNA-activated pathways. Biochem. Soc. Trans. 32: 952-956. [Medline]
  25. Hilton, D. J., J. G. Zhang, D. Metcalf, W. S. Alexander, N. A. Nicola, T. A. Willson. 1996. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA 93: 497-501. [Abstract/Free Full Text]
  26. Caput, D., P. Laurent, M. Kaghad, J. Lelias, S. Lefort, N. Vita, P. Ferrara. 1996. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor {alpha} chain. J. Biol. Chem. 271: 16921-16926. [Abstract/Free Full Text]
  27. Zurawski, S. M., P. Chomarat, O. Djossous, C. Bidaud, A. N. McKenzie, P. J. Miossec, J. Banchereau, G. Zurawski. 1995. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J. Biol. Chem. 270: 13869-13878. [Abstract/Free Full Text]
  28. Seki, Y., H. Inoue, N. Nagata, K. Hayashi, S. Fukuyama, K. Matsumoto, O. Komine, S. Hamano, K. Himeno, K. Inagaki-Ohara, et al 2003. SOCS-3 regulates onset and maintenance of Th2-mediated allergic responses. Nat. Med. 9: 1047-1054. [Medline]
  29. Smerz-Bertling, C., A. Duschl. 1995. Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor. J. Biol. Chem 270: 966-970. [Abstract/Free Full Text]
  30. Hoøejsí, V., M. Cebecauer, J. Èerny, T. Brdièka, P. Angelisová, K. Drbal. 1998. Signal transduction in leucocytes via GPI-anchored proteins: an experimental artefact or an aspect of immunoreceptor function?. Immunol. Lett. 63: 63-73. [Medline]
  31. Alfieri, J. A., A. D. Martin, J. Takeda, G. Kondoh, D. G. Myles, P. Primakoff. 2003. Infertility in female mice with an oocyte-specific knockout of GPI-anchored proteins. J. Cell Sci. 116: 2149-2155. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Hum Reprod UpdateHome page
J. Szekeres-Bartho and J. Balasch
Progestagen therapy for recurrent miscarriage
Hum. Reprod. Update, January 1, 2008; 14(1): 27 - 35.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kozma, N.
Right arrow Articles by Szekeres-Bartho, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kozma, N.
Right arrow Articles by Szekeres-Bartho, J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS